从卵巢癌cDNA文库中筛选新的肿瘤标志物  

Screening New Tumor Markers from cDNA Expression Library of Ovarian Cancer

作　　者：王颖[1] 葛海良[1] 袁明[1] 张惠珍[1] 王树军[1] 马安伦[1] 尤强[1] 周光炎[1] 

机构地区：[1]上海第二医科大学上海市免疫学研究所,上海200025

出　　处：《上海免疫学杂志》2002年第6期371-374,共4页Shanghai Journal of Immunology

基　　金：国家自然科学基金资助项目 (No 3 9970 82 4) ;上海市教委资助项目 (No S970 2 0 2 ) ;上海市科委资助项目 (No 97XD14 0 0 2 )

摘　　要：采用SEREX法筛选了自行构建的中国人卵巢癌cDNA表达文库 ,得到 2 7个阳性克隆 ,其中 3个为全长cDNA。序列分析和同源性比对结果表明所获得的 2 7个克隆分属于分化抗原、细胞结构蛋白及功能未知三类。选择其中一个全长cDNAMY OVA 13(该基因编码的蛋白是MAD2 ) ,利用基因工程方法克隆、表达和纯化得到目的蛋白 ,采用点杂交方法检测了MY OVA 13目的蛋白与正常人和肿瘤患者中的血清学反应。MY OVA 13抗体只在肿瘤组中检测到 (5 / 74 ) ,在正常组中均为阴性 ;间接ELISA测定结果显示 ,MY OVA 13抗体的水平在肿瘤组中均高于正常组 ,其中肝癌和前列腺癌组与正常组相比 ,在统计学上有显著差异 ,P值分别 <0 0 1和 <0 0 5。我们的初步结果表明MY OVA 13及其抗体具有一定的肿瘤特异性 。In order to search for new candidate tumor markers,we have utilized the method of SEREX to screen a cDNA library of an ovarian cancer cell constructed by ourselves with autologous serum In this way,we have identified 24 distinct gene clones (MY-OVA-1 to MY-OVA-27) Sequence analysis has showed that all gene clones could be classified to 3 catagories:those encoding differential antigens,those encoding structure proteins and those with unknown properties Then we evaluated the immunogenicity of MY-OVA-13 antigen using bacterially synthesized and purified proteins Serological analysis with dot-blot showed that auto-antibodies against MY-OVA-13 was only detected in tumor patients (5/74) and not detected in normal subjects (0/13) To determine the levels of these autoantibodies in sera,we further examined the sera of 84 tumor patients and 36 normal subjects with ELISA method Judged by a cut-off value of 0 620 A 490 ,none of normal subjects were positive with anti-MY-OVA-13 au to-antibody,whereas 11 patients (11/84) reached positive level for the antibody reaction Our findings indicated that the autoant ibody against MY-OVA-13 displayed some tumor-specificity If our results are confirmed by further studies,it could be potential for clinical use as a tumor marker -

关 键 词：卵巢癌 CDNA文库 肿瘤标志物 SEREX 

分 类 号：R737.31[医药卫生—肿瘤]